Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaTHway Japan Trial of palopegteriparatide in adults with hypoparathyroidism
jRCT2051210058Phase 3Completed
- Sponsor
- Ascendis Pharma
- Start
- Nov 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of palopegteriparatide in hypoparathyroidism, sponsored by Ascendis Pharma. Primary endpoint: Composite biochemical and treatment independence response at Week 26. Started Nov 2021; status: completed.
02
Drugs
palopegteriparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on jRCT2051210058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210058.